23 September 2019
IntegraGen announces 2019 first half results: Continued improvement in profitability
Welcome to IntegraGen's News and Events page. Here you will find current and archived press releases, listings of upcoming events, and news coverage about the company and some of its projects and initiatives.
Contact us if you would like more information about IntegraGen and our efforts.
11 July 2019 IntegraGen today announced the company’s sales revenue for the first half of 2019. Revenues amounted to 4,168 K€ compared to 3,624 K€ in the first half of 2018, an increase of 15%. Click here to view press release 30 June 2019 The mixed shareholders’ general meeting of IntegraGen was held on Thursday, June 13, 2019 at the Bedford Hotel’s premises at 17 rue de l’Arcade in Paris. At the end of the Combined General Meeting, (…) » 18 April 2019 IntegraGen has announced the company’s financial results for the year ending December 31, 2018. The annual accounts were approved by the Board of Directors held on April 17, 2019. Click here to view press release. 15 March 2019 05 March 2019 IntegraGen and Advanced Biological Laboratories (ABL) have announced the signing of a non-exclusive global licensing agreement enabling ABL to distribute miRpredX™, IntegraGen’s proprietary IVD CE marked diagnostic test that enables clinicians to identify metastatic colorectal cancer patients who have a higher likelihood of response to anti-EGFR therapy. 09 January 2019 IntegraGen announced today its unaudited annual sales revenue for 2018. 12 November 2018 IntegraGen has announced it is collaborating with Google Cloud for the implementation of IntegraGen’s advanced genomic analysis tools, SIRIUS™ and MERCURY™ into the Google Cloud Platform. This partnership will enable widespread online availability, rapid data transfer and enhanced data security to clinicians and researchers utilizing these analytical tools. 21 October 2018 Analysis of PETACC-8 clinical trial samples demonstrates company’s proprietary miR-31 microRNA biomarkers identifies subpopulations of patients with resected stage III colon cancer who benefit from the addition of cetuximab to FOLFOX adjuvant therapy IntegraGen announced today that it presented data on the company’s proprietary miR-31 (…) » 20 September 2018 IntegraGen has announced today its financial results for the first half of semester 2018 with the accounts having been examined by the company’s Board of Directors on September 20, 2018.
IntegraGen reports sales of € 4.2 million in the first half of 2019, up 15%
Press release on General Assembly voting results
IntegraGen Reports 2018 Annual Results
IntegraGen to present at 6th annual Portzamparc MidCap Conference – April 10, 2019
Come and meet us at the #ConfMidCap2019 @Portzamparc, April 10th!
IntegraGen and Advanced Biological Laboratories sign global licensing agreement for the commercialization of miRpredX test
IntegraGen Reports Revenue of €6.9 million for 2018 (+11%) and Cash Position of €4.0 million
IntegraGen Announces Collaboration with Google Cloud to Offer Large Scale Genomic Analysis Tools for Clinicians and Medical Researchers
IntegraGen presents new data expanding application of miR-31 to stage III colon cancer during ESMO 2018
IntegraGen Reports Financial Results for 1st Half of 2018
